Chapter from the book *Medical Complications of Type 2 Diabetes*

Downloaded from: http://www.intechopen.com/books/medical-complications-of-type-2-diabetes

Interested in publishing with InTechOpen?
Contact us at book.department@intechopen.com
Type 2 Diabetes and Pancreatic Cancer – A Possible Reason

Parviz M Pour
UNMC/Eppley Cancer Center, University of Nebraska Medical Center, Omaha, USA

1. Introduction

Nearly 80% patients of pancreatic cancer (PC) have impaired glucose metabolism, either frank diabetes or impaired glucose tolerance (IGT)\(^1,2\) and the majority of diabetes associated with PC is diagnosed either concomitantly or during the two years before the diagnosis of PC\(^3\). Karmody and Kyle reported that PC was diagnosed within one year from the onset of the diabetes in 40 out of 51 patients (78.4%)\(^4\). According to Gullo et al.\(^5\), diabetes in patients with PC is frequently (56.1%) of the recent onset type and is presumably caused by the tumor. In this study, in 43.9% of the patients, the diagnosis of diabetes preceded the diagnosis of PC by three years and in 37.2% it was five or more years. In a more recent study, the diagnosis of PC and diabetes was made concomitantly or shortly before the tumor diagnosis in 65% of the patients\(^6\). Presently, a number of investigators consider diabetes to be a clinical manifestation of PC rather than a risk factor for the disease. This view is in sharp contrast to views that diabetes is a predisposing factor for PC. In many retrospective case-control and prospective cohort studies, an association between longstanding diabetes and an increased rate of subsequent death from PC was indicated\(^7-9\). In recent studies, however, when the latency period between the onset of diabetes and PC was considered, the issue became muddled. In some studies, when the patients with short latency periods were excluded from the sample size, the relative risk of diabetes for PC was markedly diminished\(^3-5\). In another population-based case control study, a significant positive trend in risk for PC was detected (\(p=0.016\)) in patients with diabetes diagnosed ten or more years prior to cancer detection\(^10\). The meta-analysis of more than 20 epidemiologic studies indicated the relative risk of PC for diabetics diagnosed at least five years prior to the diagnosis of cancer as 2.0\(^11\). In two prospective cohort studies with more than 20 years follow-up, an increased risk was found among subjects with high post-load plasma glucose levels\(^12,13\). In the latter study, the risk was 2.2-fold higher for participants whose post-load glucose level was at least 200 mg/dl at baseline compared with those with the levels equal or less than 119 mg/dl. These studies evidently show that glucose intolerance may preceed the onset of PC rather than just being a consequence.

The major problem of such epidemiological studies is that the exact onset time of both diabetes and PC is obscure and insidious. The non-insulin-dependent diabetes mellitus may take more than seven years before it is clinically diagnosed\(^14\). The latency of PC is also unclear, and the development of some cancers seems to take ten years\(^15\) or even longer\(^16\). Undiagnosed diabetes or PC may have proceeded for many years without diagnosis. For
these reasons, estimation of the exact duration needed to conclude that the diabetes 
occurred before or after the development of PC is difficult. 
The incidental pancreatic cancer detection indicates that this cancer can remain silent for a 
considerable time or grow very slowly. Nevertheless, the notion that diabetes is a 
predisposing factor for PC remains questionable. Data gained from experimental pancreatic 
cancer model unquestionably indicate that the IGT is associated with the development of 
pancreatic cancer. We performed the following study to understand reasons for the 
development of diabetes in pancreatic cancer.

Eight-week-old outbred Syrian Golden hamsters (SGH) of the Eppley colony were used. 
They were housed in the centralized Comparative Medicine Animal Facilities, an AAALAC 
International accredited animal facility, in plastic cages on corn cob bedding (Bed-O-Cobs, 
The Anderson Cob Co., Maumee, OH) under standard laboratory conditions (temperature, 
21 ± 2°C; humidity, 40±5%; light/dark cycle, 12 hr/12 hr; 10x air changes/hr). They were 
fed a commercial diet (Wayne Lab Blox, Allied Mills, Chicago, IL) and had free access to tap 
water. The maintenance and humane treatment of the animals followed the guidelines of the 
UNMC Animal Care and Use Committee.

For the determination of glucose metabolism, five randomly selected 8-week-old male SGH 
with an average weight of 100 g were treated with the potent pancreatic carcinogen, N-
nitrosobis(2-oxopropyl)amine (BOP) at a dose of 10 mg/kg body weight once a week for 
four weeks. The same number of animals served as controls. Ten weeks after the last BOP 
injection, at the time generally proliferative and hyperplastic lesions appears, glucose 
tolerance was determined in all hamsters as reported. Following the test the pancreas of 
all hamsters was examined histologically.

The presence of Insulin and glucagon assay in pancreatic juice and plasma was investigated 
in thirty 8-week-old male SGH with an average weight of 100g, who were treated with BOP 
as above. Thirty hamsters of the same age and weights were served as controls. In each 
group, the insulin content of pancreatic juice and plasma were assayed in 10 hamsters each 
at 12, 16 and 20 weeks after the last BOP injection as reported.

From our tumor archive, the pancreatic tissue of 30 SGH with tumors induced by BOP at a 
dose of 10 mg/kg body weight weekly for six weeks were examined immunohistochemically using antibodies to insulin, glucagon, somatostatin and PP with a 
multilabeling technique, developed in our laboratory. Sixty seven surgically removed 
human pancreatic cancer specimens from our previous study were also subjected to 
immunohistochemical examination for the expression of insulin, glucagon, somatostatin and 
PP as above.

The results of these experiments showed that at 10 weeks after BOP treatment plasma insulin 
level did not change compared to that in untreated control hamsters, whereas the glucose level 
increased significantly at 120 minutes (Fig. 1). Histologically focal or multi-focal ductal and 
ductular hyperplasia and in one hamster ductal in situ carcinoma were found. As in our 
previous studies, intrainsular ductular proliferation were found in all hamsters.

Insulin assay in pancreatic juice and plasma: As summarized in Table 1, although at week 12 
the plasma insulin concentration did not differ from the control value, it decreased by one-
half at week 16 but was significantly lower at week 20. On the contrary the level of insulin in 
pancreatic juice increased successively and was significantly decreased significantly and 
successively while juice insulin level conversely increased significantly by time (Table 1). 
The glucagon level in plasma did not change significantly at either point, whereas its level 
increased significantly and successively and was the highest at 20 week (Table 2).
Proliferative and hyperplastic ductal lesions were found at week 12 and 16 and a few in situ carcinomas and a microcarcinoma at week 20. A remarkably large number of endocrine cells (primarily \(\beta\)-cells) were found in hyperplastic ducts and in the microcarcinoma (Fig. 2), as well as some of hybrid type containing endocrine granules and mucin. Immunohistochemically in all hyperplastic, premalignant and malignant lesions in human tissues, scattered or generally a large number of endocrine cells, composed primarily of insulin and glucagon, and less frequently somatostatin cells were found in the basal layer, but sometimes within the papillary fonts (Fig. 2). Insulin immunoreactivity was also present in the luminal content of hyperplastic ducts and malignant glands.

![Glucose tolerance test in SGH treated with BOP weekly for 6 weeks (red) and in untreated controls (blue)](image)

**Fig. 1.** Glucose tolerance test in SGH treated with BOP weekly for 6 weeks (red) and in untreated controls (blue)

| Week | Plasma  | Juice   |
|------|---------|---------|
| 12   | 6.07±1.96 | 4.28±1.40 |
| 16   | 3.02±1.67 | 5.07±2.05 |
| 20   | 2.52±0.12* | 8.43±2.40* |

*p<0.05 compared to control values

**Table 1. Insulin Levels (\(\mu\)U/ml)**

| Week | Plasma  | Juice   |
|------|---------|---------|
| 12   | 0.62±0.07 | 25.8±4.40* |
| 16   | 3.02±1.67 | 35.4±2.19* |
| 20   | 2.52±0.12* | 39.4±3.10* |

*p<0.001 compared to control values

**Table 2. Levels of Glucagon (ng/ml)**
Fig. 2. Endocrine cells in pancreatic cancer. a) hamster adenocarcinoma. Insulin (brown), glucagon (blue), somatostatin (red). Multilabeling technique x65. B) Insulin cells in papillary fond and in the basal layer of the malignant epithelial cells of a human intraductal cancer. x50. c) insulin cells in human pancreatic cancer. x50; d) Insulin cells in proliferative ductal lesion in a hamster. x50; e) a large number of endocrine cells in human pancreatic cancer. insulin (blue); glucagon (brown); somatostatin (red). Multilabeling technique x50), f. endocrine cells covering the whole length of the basal layer of a tumor in a patient. X45.

Similar to the findings in the hamster tissue, insulin, glucagon and, less frequently, somatostatin cells were found in hyperplastic, but in extremely large numbers in well differentiated malignant glandular structures in human PC. In many areas the number of endocrine cells exceeded the number of malignant cells in glandular structures (Fig. 2). Remarkably, in the lumen of several malignant glands, many cells and debris immunoreactive with anti-insulin were identified (Fig. 3).
Experimental models have opened avenues for studying areas of research that are impossible to obtain from humans. Among the existing pancreatic cancer model, SGH has provided the most relevant model for translational research. Morphologically, the wide spectrum of human pancreatic cancer, including the rare tumors, is reproducible in this species. Most human pancreatic cancer-associated antigens, including blood group antigens, as well as carbohydrate antigens are also expressed in cancers induced in hamsters. Most genetic mutations, methylation or deletions found in human pancreatic cancer, including the K-ras, p16^{INK4A}, DPC4/SMAD4, DCC and FHit are also detected in hamster pancreatic

Fig. 3. Cells and debris immunoreactive with anti-insulin in the lumen of malignant gland structures. β cells are also present in the base of the epithelium (arrows). X65
cancer. Remarkably, the deletion of chromosome Y, frequently found in human pancreatic cancer occurs also in the hamster tumor. Moreover, among other existing PC models, including transgenic mouse models, the hamster model is the only model that shows insulin secretion abnormality, occurring in over 80% of PC patients.

Based on these similarities, the model offered a useful tool to understand the existing controversial view on the association between type 2 diabetes and PC. Although SGH are not prone to diabetes, under certain diet they present pre-diabetic condition such as peripheral insulin resistance, which, as in humans, can be controlled by Metformin. Because in this model initial alteration occurs within the islets by formation of intrinsular ductular structures, which progressively leads to the development of cancer that destroys the islet, studies were performed to explore the effect of such alteration on glucose metabolism.

Ahrén and Andrén-Sandberg, were the first to demonstrate the abnormality in glucose tolerance occurs at the very early stages of carcinogenesis. In their study, where the glucose tolerance and insulin secretion during the development of pancreatic cancer was examined, the glucose tolerance and glucose-stimulated insulin secretion were found to be normal at 6, 12, and 18 weeks after start of carcinogen treatment compared with age-matched saline-injected controls. By contrast, after 24, 30, and 42 weeks, at which time proliferative and neoplastic lesions develop, an exaggerated plasma-glucose response and a concomitant impaired plasma-insulin response occurred during the glucose infusion (P < 0.05). Hence, it was conclude that the development of pancreatic cancer in this model is accompanied by glucose intolerance and impaired insulin secretion, and that these effects occur concomitantly with the development of cancer. In the present study using the same experimental protocol confirmed the development of IGT (Fig. 1). At the time of proliferative and hyperplastic ductal lesions.

Reasons for examining the pancreatic juice during pancreatic cancer development was based on our findings of insulin-like and growth hormone-like substances in pancreatic juice of untreated hamsters. Literature search revealed that this discovery was not unique to hamsters and has been reported in pancreatic juice of humans and laboratory species supporting the assumption for the existence of an insuloacinar portal system to regulate exocrine pancreatic functions by islet hormones. The question on the mechanism of whether insulin enters into the ductal system by passive or active mechanism has remained illusive. Since CCK is a powerful stimulant for the release of insulin and somatostatin, the greater effect of CCK infusion in eliciting a higher concentration of immunoreactive insulin and somatostatin in the pancreatic juice indicated that the hormones in the juice derive directly from the islets to the ductules. This view is further supported by our electron microscopical findings that revealed the likelihood of the direct route of insulin into the ductal lumen, as insulin granules were found in large numbers in peri ductal and peri vascular spaces, suggesting that insulin secretion occurs into both blood vessels and ductal lumen. Hence, It appears that in the normal condition pancreatic hormones is secreted into blood vessels and ductal system possibly in a controlled defined proportion. The physiological importance of insulin secretion via ductal system as a potent growth factor for gastrointestinal epithelium has been discussed by us elsewhere.

As stated earlier, the initial development of ductular structures within the islets with gradual proliferation, malignant alteration and gradual replacement of the islets suggested alteration in insulin secretion. The development of mixed ductular-insular structures, suggesting intimate communication between islet cells and ductal cells prompted us to
examine the pancreatic juice of hamsters during tumor development. In a study, we measured the concentrations of insulin, glucagon, somatostatin, and islet amyloid polypeptide (IAPP) in plasma and secretin-stimulated pancreatic juice at 12 and 27 weeks after the treatment of hamsters with BOP. At 12 weeks after BOP, plasma glucagon levels were significantly increased. An exaggerated plasma-glucose response were observed at 27 but not at 12 weeks after BOP. Plasma IAPP concentrations, but not glucagon or somatostatin, were elevated at 27 weeks. Tissue concentrations of IAPP were substantially reduced in BOP-treated hamsters at 27 weeks. The study, nevertheless, showed that islet hormone changes accompany the early development of pancreatic tumors in this model. Thus, the hormone changes and apparent insulin resistance resemble the metabolic changes found in humans with pancreatic cancer.

In the present study, a dramatic increase of insulin and glucagon levels was found in pancreatic juice of hamsters during pancreatic carcinogenesis indicating an alteration in islet function causing a shift in insulin secretion. Indeed, in both humans and hamsters islet cells during cancer development undergo alterations, including transdifferentiation of hormone producing cells into duct-like elements that could explain the reduction in the level of plasma insulin. The level of insulin in pancreatic juice, however, is maintained and further increased by another event. In the hamster model and in human pancreatic cancer subjects as well, normal ducts, but more often altered ducts and especially malignant glandular structures show a large number of endocrine cells immunoreactive to anti-insulin and anti-glucagon antibodies, embedded within the epithelium. In some cases, the number of endocrine cells exceeded the number of the malignant epithelial cells. Within the malignant epithelium as well as in the lumen of several malignant glands many cells immunoreactive with anti-insulin were identified. The finding suggested that insulin-containing cells, produced by malignant glands, are expelled into the glandular lumen, as are malignant cells, and thus into the pancreatic juice. Remarkably, we could not find any study examining the presence of hormones in pancreatic juice of pancreatic cancer patients, although, as stated earlier, endocrine hormones in pancreatic juice has been recognized many years ago in patients without pancreatic cancer.

The above information along with our current results let us conclude that the induction of proliferative and malignant lesions in the pancreas is associated with IGT, which also occurs in the majority of human cases. In fact, a study in Japan has shown that the incidence of IGT in PC patients was dependent on the size of cancer; in patients with tumor size >2.1 cm, the incidence of IGT was 56%, in tumors of 2.0 cm in size, it was 36%, in those with 1.1-2 cm, it was 39% and in 7 patients with tumors <1 cm, it was 28%. In the latter case, the abnormality was the only clinically detectable abnormality. Remarkably, the determination of IGT has not yet been adapted as a routine test in the United States possibly awaiting additional validating data to be presented.

2. Conclusion

In SGH the development of PC is associated with IGT, as has also been suggested in humans. 2) In the normal pancreas, insulin is also secreted into pancreatic juice, both in humans and in animals. 3) The reduced level of insulin in blood but its increased concentration in pancreatic juice during pancreatic carcinogenesis is likely responsible for the IGT and diabetes, and 4) the development of IGT, along with hypersecretion of insulin in pancreatic juice could present early marker for PC.
3. References

[1] Permert J, Ihse I, Jorfeldt L, von Schenck H, Arnqvist HJ, Larsson J. Pancreatic cancer is associated with impaired glucose metabolism. Eur J Surg 1993;159:101-7.

[2] Schwarts SS, Zeidler A, Moossa AR, Kuku SF, Rubenstein AH. A prospective study of glucose tolerance, insulin, C-peptide, and glucagon responses in patients with pancreatic carcinoma. Am J Dig Dis 1978;23:1107-14.

[3] Gullo L, Pezzilli R, Morselli-Labate AM. Diabetes and the risk of pancreatic cancer. N Engl J Med 1994;331:81-4.

[4] Karmody AJ, Kyle J. The association between carcinoma of the pancreas and diabetes mellitus. Br J Surg 1969;56:362-4.

[5] Gullo L. Diabetes and the risk of pancreatic cancer. Ann Oncol 1999;10 Suppl 4:79-81.

[6] Chow WH, Gridley G, Nyren O, Linet MS, Ekbom A, Fraumeni JF, Jr., Adami HO. Risk of pancreatic cancer following diabetes mellitus: a nationwide cohort study in Sweden. J Natl Cancer Inst 1995;87:930-1.

[7] Silverman DT, Swanson CA, Gridley G, Wacholder S, Greenberg RS, Brown LM, Hayes RB, Swanson GM, Schoenberg JB, Pottern LM, Schwartz AG, Fraumeni JF, Jr., Hoover RN. Dietary and nutritional factors and pancreatic cancer: a case-control study based on direct interviews. J Natl Cancer Inst 1998;90:1710-9.

[8] Cuzick J, Babiker AG. Pancreatic cancer, alcohol, diabetes mellitus and gall-bladder disease. Int J Cancer 1989;43:415-21.

[9] Ragozzino M, Melton LJ, 3rd, Chu CP, Palumbo P. Subsequent cancer risk in the incidence cohort of Rochester, Minnesota, residents with diabetes mellitus. J Chronic Dis 1982;35:13-9.

[10] Silverman DT. Risk factors for pancreatic cancer: a case-control study based on direct interviews. Teratog Carcinog Mutagen 2001;21:7-25.

[11] Everhart J, Wright D. Diabetes mellitus as a risk factor for pancreatic cancer. A meta-analysis. JAMA 1995;273:1605-9.

[12] Smith GD, Egger M, Shipley MJ, Marmot MG. Post-challenge glucose concentration, impaired glucose tolerance, diabetes, and cancer mortality in men. Am J Epidemiol 1992;136:1110-4.

[13] Gapstur SM, Gann PH, Lowe W, Liu K, Colangelo L, Dyer A. Abnormal glucose metabolism and pancreatic cancer mortality. JAMA 2000;283:2552-8.

[14] Harris MI, Klein R, Welborn TA, Knuiman MW. Onset of NIDDM occurs at least 4-7 yr before clinical diagnosis. Diabetes Care 1992;15:815-9.

[15] Brat DJ, Lillemoe KD, Yeo CJ, Warfield PB, Hruban RH. Progression of pancreatic intraductal neoplasias to infiltrating adenocarcinoma of the pancreas. Am J Surg Pathol 1998;22:163-9.

[16] Michaud DS, Fuchs CS. Obesity and pancreatic cancer: overall evidence and latency period. Cancer Epidemiol Biomarkers Prev 2005;14:2678; author reply 2678-9.

[17] Kimura W, Morikane K, Esaki Y, Chan WC, Pour PM. Histologic and biologic patterns of microscopic pancreatic ductal adenocarcinomas detected incidentally at autopsy. Cancer 1998;82:1839-49.

[18] Ahren B, Andren-Sandberg A. Glucose tolerance and insulin secretion in experimental pancreatic cancer in the Syrian hamster. Res Exp Med (Berl) 1993;193:21-6.
Type 2 Diabetes and Pancreatic Cancer – A Possible Reason

[19] Helgeson AS, Lawson T, Pour P. Exocrine pancreatic secretion in the Syrian golden hamster Mesocricetus auratus--III. Effects of carcinogen administration and development of pancreas cancer. Comp Biochem Physiol C 1984;77:191-7.

[20] Permert J, Herrington M, Kazakoff K, Pour PM, Adrian TE. Early changes in islet hormone secretion in the hamster pancreatic cancer model. Teratog Carcinog Mutagen 2001;21:59-67.

[21] Pour PM, Kazakoff K, Dulaney K. A new multilabeling technique for simultaneous demonstration of different islet cells in permanent slides. Int J Pancreatol 1993;13:139-42.

[22] Pour PM, Schmied BM, Ulrich AB, Friess H, Andre-Sandberg A, Buchler MW. Abnormal differentiation of islet cells in pancreatic cancer. Pancreatology 2001;1:110-6.

[23] Bardi G, Johansson B, Pandis N, Mandahl N, Bak-Jensen E, Andre-Sandberg A, Mitelman F, Heim S. Karyotypic abnormalities in tumours of the pancreas. Br J Cancer 1993;67:1106-12.

[24] Johansson B, Bardi G, Heim S, Mandahl N, Mertens F, Bak-Jensen E, Andre-Sandberg A, Mitelman F. Nonrandom chromosomal rearrangements in pancreatic carcinomas. Cancer 1992;69:1674-81.

[25] Takahashi M HM, Mutoh M, Wakabayashi K, Nakagama H. Experimental Animal Models of Pancreatic Carcinogenesis for Prevention Studies and Their Relevance to Human Disease. Cancers 2011;3:582-602.

[26] Schneider MB, Matsuzaki H, Haorah J, Ulrich A, Standop J, Ding XZ, Adrian TE, Pour PM. Prevention of pancreatic cancer induction in hamsters by metformin. Gastroenterology 2001;120:1263-70.

[27] Pour PM, Standop J, Batra SK. Are islet cells the gatekeepers of the pancreas? Pancreatology 2002;2:440-8.

[28] Bailey CJ, Flatt PR, Atkins TW, Matty AJ. Immunoreactive insulin in bile and pancreatic juice of rat. Endocrinol Exp 1976;10:101-11.

[29] Conlon JM, Rouiller D, Boden G, Unger RH. Characterization of immunoreactive components of insulin and somatostatin in canine pancreatic juice. FEBS Lett 1979;105:23-6.

[30] Ertan A, Taminato T, Akdamar K, Ryan J, Agrawal NM, Schally AV, Arimura A. Immunoreactive somatostatin in human pancreatic secretion. J Clin Endocrinol Metab 1981;52:589-91.

[31] Fischer U, Hommel H, Ziegler M, Nowak W, von Dorsche HH. The mechanism of insulin secretion after oral glucose administration. VIII. Pancreatic juice insulin excretion after glucose loading and meal ingestion in normal and vagotomized dogs. Endokrinologie 1976;68:327-37.

[32] Prinz RA, Kirsteins L, Connick E, Paloyan E, Lawrence AM. Insulin and glucagon in human pancreatic exocrine fluid. Horm Metab Res 1980;12:38-9.

[33] Runzi M, Muller MK, Schimiczek M, von Schonfeld J, Goebell H. Identification of somatostatin-14 and -28 in rat pancreatic juice by a new HPLC method. Int J Pancreatol 1992;11:19-22.

[34] Sarfati PD, Green GM, Brazeau P, Morisset J. Presence of somatostatin-like immunoreactivity in rat pancreatic juice: a physiological phenomenon. Can J Physiol Pharmacol 1986;64:539-44.
[35] Ipp E, Dobbs RE, Harris V, Arimura A, Vale W, Unger RH. The effects of gastrin, gastric inhibitory polypeptide, secretin, and the octapeptide of cholecystokinin upon immunoreactive somatostatin release by the perfused canine pancreas. J Clin Invest 1977;60:1216-9.

[36] Pour PM, Hauser RE. Exocrine secretion of pancreatic hormones: possible mechanisms. Int J Pancreatol 1987;2:277-87.

[37] Ariyama J. Abnormal glucose tolerance in patients with early pancreatic carcinoma. Int J Pancreatol 1994;16:91.
Obesity and type 2 diabetes are increasing worldwide problems. In this book we reviewed insulin secretion in both healthy individuals and in patients with type 2 diabetes. Because of the risk associated with progression from insulin resistance to diabetes and cardiovascular complications increases along a continuum, we included several chapters on the damage of endothelial cells in type 2 diabetes and genetic influences on endothelial cell dysfunction. Cardiovascular complications occur at a much lower glucose levels, thus a review on the oral glucose tolerance test compared to other methods was included. The medical conditions associated with type 2 diabetes such as pancreatic cancer, sarcopenia and sleep disordered breathing with diabetes were also discussed. The book concludes with several chapters on the treatments for this disease offering us hope in prevention and successful alleviation of the co-morbidities associated with obesity and type 2 diabetes.

How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:

Parviz M Pour (2011). Type 2 Diabetes and Pancreatic Cancer – A Possible Reason, Medical Complications of Type 2 Diabetes, Dr. Colleen Croniger (Ed.), ISBN: 978-953-307-363-7, InTech, Available from: http://www.intechopen.com/books/medical-complications-of-type-2-diabetes/type-2-diabetes-and-pancreatic-cancer-a-possible-reason